LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $15.00

LifeStance Health Group (NASDAQ:LFST) had its price target lifted by Barclays from $13.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. BTIG Research raised their price objective on LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Wall Street Zen cut LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Finally, KeyCorp upped their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.88.

LifeStance Health Group Trading Down 0.2%

LFST stock opened at $12.97 on Thursday. LifeStance Health Group has a 52 week low of $4.77 and a 52 week high of $13.28. The company has a market capitalization of $4.96 billion, a PE ratio of 99.78 and a beta of 1.22. The company’s 50-day simple moving average is $11.67 and its 200 day simple moving average is $9.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business’s revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.01) EPS. As a group, sell-side analysts anticipate that LifeStance Health Group will post 0.16 earnings per share for the current year.

Insider Activity

In other LifeStance Health Group news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the completion of the transaction, the insider directly owned 98,101,407 shares in the company, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the sale, the director owned 539,763 shares of the company’s stock, valued at $5,467,799.19. The trade was a 62.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 14,671,917 shares of company stock worth $155,493,415. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Assetmark Inc. increased its holdings in LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after purchasing an additional 1,367 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of LifeStance Health Group by 7.7% during the 2nd quarter. Allworth Financial LP now owns 26,532 shares of the company’s stock worth $284,000 after buying an additional 1,889 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of LifeStance Health Group by 1.6% during the 4th quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after buying an additional 1,966 shares in the last quarter. Vident Advisory LLC grew its position in shares of LifeStance Health Group by 12.7% during the 2nd quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after buying an additional 2,447 shares during the period. Finally, Xponance LLC grew its position in shares of LifeStance Health Group by 26.4% during the 4th quarter. Xponance LLC now owns 13,144 shares of the company’s stock worth $93,000 after buying an additional 2,745 shares during the period. Institutional investors and hedge funds own 85.50% of the company’s stock.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Barclays raised its price target for LifeStance Health Group from $13 to $15 and maintained an “overweight” rating, implying further upside from the stock’s recent level. Barclays price target report
• Positive Sentiment: Zacks highlighted LFST as a strong momentum candidate, reinforcing investor interest after the shares’ substantial appreciation over the past year. Zacks momentum stock analysis
• Positive Sentiment: The company’s latest quarterly results showed strong operating momentum: revenue increased 26.1% year over year to $435.4 million, while adjusted earnings of $0.06 per share exceeded expectations of $0.03. The company is also projected to remain profitable for the full year.
• Neutral Sentiment: LifeStance announced a secondary offering alongside a share repurchase program. The repurchase could help absorb some of the shares being offered and support the stock, although the overall effect depends on the offering size and terms. LifeStance secondary offering and share repurchase announcement
• Neutral Sentiment: Brokerages collectively rate LFST a “Moderate Buy,” suggesting generally favorable expectations but not unanimous conviction.
• Negative Sentiment: The secondary offering may create additional share supply and weigh on the stock in the near term, particularly after its sharp run-up. The stock also trades at a high valuation—roughly 100 times earnings—leaving it sensitive to changes in growth expectations.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a behavioral health care company that provides outpatient mental health services through in-person and virtual appointments. Its platform connects patients with psychiatrists, psychologists, psychiatric nurse practitioners, therapists and other licensed clinicians.

The company offers services that may include psychotherapy, psychiatric evaluations, medication management and treatment for conditions such as anxiety, depression, attention-deficit/hyperactivity disorder and other behavioral health needs.